The decentralized research organization Care Access Research has teamed up with AstraZeneca to support the Phase III clinical trial for AZD7442, AstraZeneca’s long-acting monoclonal antibody combination for the potential prevention of COVID-19.
Using Care Access’s Mobile Sites On Demand, the two will develop, deploy and manage clinical research sites across the country to assess the safety and efficacy of AZD7442 for post-exposure prophylaxis and preemptive treatment.
“Traditional methods limit who can participate in a clinical trial and how quickly we can complete the clinical trial,” said Ahmad Namvargolian, CEO of Care Access, in a statement. “We are pleased to provide AstraZeneca the innovative capabilities they need to expedite clinical research operations for this important COVID-19 treatment candidate.”
The trial will include approximately 1,125 participants over the age of 18 in the U.S. and U.K. who have been exposed to COVID-19. It will include people living or working at long-term care facilities as well as those in industrial and military settings.
In a new multi-year agreement, Komodo Health will integrate longitudinal, de-identified, real-world patient data from Blue Health Intelligence into its Healthcare Map, which tracks patient encounters across the U.S. healthcare system.
The database will capture patient journeys from more than 325 million de-identified individuals. Healthcare stakeholders can use these journeys to understand gaps in care, identify opportunities for early intervention, and pinpoint clinical trial candidates, among other things.
“With this partnership, life sciences companies will have a choice in how they access Blue Health Intelligence's data and resulting aggregated insights for the first time,” said Dr. Arif Nathoo, the CEO and cofounder of Komodo Health, in a statement. “Integrated into Komodo’s Healthcare Map, these insights will arm life sciences companies with the critical intelligence and real-world data needed to truly understand what’s happening in healthcare as they advance therapeutics and vaccines."
Papa’s on-site and virtual-companion health services are now available to health plans and providers through the Healthify social determinants of health platform.
"The COVID-19 pandemic has opened the eyes of people across the country to the negative impact being separated from family and friends can have on a person's physical, mental and emotional wellbeing," said Manik Bhat, the founder and CEO of Healthify, in a statement.
"Until now it has been challenging to identify seniors at risk for social isolation and loneliness and intervene to provide support. Together with Papa, we're making it easy for healthcare organizations to seamlessly integrate companion services into their patient care offerings and help improve health outcomes."
On the Healthify platform, health plans and providers can identify, search and coordinate social services for their members and patients. Now, through its partnership with Papa, users can request Papa Pals to offer companionship and assistance with everyday tasks for older adult members.
Allscripts, an electronic health records vendor, has partnered with the U.S. Orthopedic Alliance to create an orthopedic services technology platform for providers nationwide.
With Allscripts’ healthcare IT infrastructure and USOA’s industry experience, the two will collaborate on a platform that intends to: help orthopedic practices scale, improve EHR implementation timelines, provide evidence-based guidelines to support evolving clinical protocols and create community-wide connectivity with value-based care analytics.
"Combining the extensive industry expertise of USOA with Allscripts’ vast technology expertise and broad use in the independent physician space creates a compelling platform for orthopedic practitioners that want to access health information technology solutions only the largest health systems could afford," said Leah Jones, SVP and general manager of Allscripts’ ambulatory business unit, in a statement.
